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Summary The Myc oncoprotein is associated with cell proliferation and is often down-regulated during cell
differentiation. The related Mad transcription factor, which antagonises Myc activity, is highly expressed in
epidermal keratinocytes. Mad also inhibits cell proliferation in vitro. To study Mad expression in keratinocyte
proliferation and differentiation, we have analysed Mad RNA expression in regenerating and hyperproliferative
epidermal lesions and epidermal tumours of varying degrees of differentiation using the RNA in situ
hybridisation and RNAase protection techniques. Mad was strongly expressed in differentiating suprabasal
keratinocytes in healing dermal wounds and in benign hyperproliferative conditions, but also in squamous cell
carcinomas, in which the keratinocytes retain their differentiation potential. However, Mad expression was lost
in palisading basal carcinoma cells and poorly differentiated squamous cell carcinomas, which lacked the
epithelial differentiation marker syndecan-1. We therefore suggest that Mad expression is closely associated
with epithelial cell differentiation, and that this association is retained in epithelial tumours of the skin.
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Epithelial cell proliferation and differentiation is a complex
process. The regulation of genes encoding structural proteins,
such as keratins, during epithelial cell growth and differentia-
tion is relatively well known (Fuchs, 1993). However, less is
known about the roles of specific transcription factors, for
example in keratinocyte proliferation and differentiation
(Fuchs, 1990). The Myc oncoprotein and transcription
factor regulates cell growth and apoptosis (Alitalo et al.,
1992; Amati et al., 1993; Cantley et al., 1991; Morgenbesser
and Depinho, 1994; Vastrik et al., 1995). Induction of cell
differentiation is in general associated with down-regulation
of Myc mRNA, although the expression of the myc genes in
many cases is compatible with differentiation (Liischer and
Eisenman, 1990). Mad is a recently cloned basic region
helix-loop-helix-leucine zipper (bHLHZip) transcription
factor that competes with Myc for dimerisation with Max, a
constitutively expressed bHLHZip protein (Blackwood and
Eisenman, 1991; Vaistrik et al., 1993). In contrast to the
Myc-Max complex, which transactivates gene expression,
the Mad -Max complex suppresses transcription from
promoter constructs containing the Myc target sequence
CACGTG (Ayer et al., 1993). The relative abundance of
Mad and Myc could thus determine the activity of Myc
target genes involved in the control of cell proliferation and
differentiation (Ayer and Eisenman, 1993). In particular, the
expression of Mad may be required for normal differentiation
by counterbalancing the growth-promoting effects of Myc.
Changes in the differentiation of epidermal keratinocytes
and in the maturation of epidermal cell layers occur during
wound healing and tumorigenesis in the epidermis. Wound
healing includes responses involving increased expression of
several growth factors and cytokines, keratinocyte migration,
proliferation and modulation of pericellular matrix biosynth-
esis and deposition. For example, syndecan-1, which
represents a family of cell-surface proteoglycans that
influence cellular proliferation and differentiatiion is in-
creased during wound healing (Mali et al., 1990), but lost
in carcinomas and during the development of severe dysplasia
(Inki et al., 1994).
Skin tumour formation in the mouse induced by repeated
applications of polycyclic hydrocarbons, such as 9,10-
dimethylbenz(a)anthracene (DMBA) or UV irradiation can
be used as an in vivo model in the study of different stages of
neoplastic disease (Stenback, 1978). This tumour model
progresses in a series of steps, from the formation of
hyperplastic, regressing lesions to dysplasia and papillomas,
and ultimately highly malignant squamous cell carcinomas
(Yuspa et al., 1991; Bjelogrlic et al., 1994; Stenback, 1978).
The neoplastic cell populations are characterised by altered
keratin expression, increased expression of proliferating cell
nuclear antigen (PCNA), decrease in the basement membrane
constituents laminin and collagen IV, and an increase in the
p53 oncoprotein in the malignant cells (Yuspa et al., 1991;
Bjelogrlic et al., 1994).
We have recently observed that Mad mRNA is strongly
expressed in the differentiating epithelia of mouse embryos
(Vastrik et al., 1995). Mad signals are abundant in suprabasal
differentiating cell layers, but not in the basal proliferating
cells of either skin or gut epithelium. This suggests that
during re-epithelialisation, Mad expression may be sequen-
tially altered. This selective expression may then be disrupted
or completely lost during malignant epithelial progression. In
this study we have analysed Mad expression in adult mouse
where hyperproliferative and malignant states were induced
by full-thickness wounds and by DMBA treatment of the
skin, respectively. We have also studied human epidermal
tumours such as basal cell and squamous cell carcinomas and
melanomas. We have localised Mad mRNA to the upper
epidermal cell layers, where the keratinocytes differentiate
irreversibly. We observed a similar expression pattern in
carcinomas, where the malignant cells retain differentiation
capacity, whereas anaplastic tumours consisting of proliferat-
ing cells without signs of differentiation are negative for Mad
mRNA.
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Materials and methods
Generation of skin tumours in mice
NMRI mice were exposed to DMBA, 50 mg twice a week for
10 weeks and then sacrificed at the termination of the study.
Animal treatment, maintenance and conduction of the study
followed standard protocols (Bremner et al., 1994; Bjelogrlic
et al., 1994; Yuspa, 1994). The facility was supervised by the
University of Oulu Animal Welfare Committee and followed
established guidelines. Samples for histological, immunohis-
tochemical and RNA in situ studies were excised from the
skin of normal mice as a control, and from the skin lesions
obtained after wounding or carcinogen treatment (Werner et
al., 1992).
Figure 1 RNA in situ analysis of Mad expression in newborn and adult mouse skin. Darkfield (a,c,e and g) and lightfield (b, d, f
and h) exposures are shown. a and b are from newborn mouse, c-h from adult mouse. c and d represent areas of normal thick skin,
e and h are from an area of thin skin. a, c and e represent results of hybridisations with the Mad antisense probe, whereas the inset
in c shows control hybridisation with the Mad sense probe. g shows hybridisation of an adjacent section with the c-Myc antisense
probe. Bar= 0. mm.
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RNAase protection assay
The RNAase protection assay was carried out as described
by Vastrik et al. (1995). The mouse Mad antisense cRNA
probe was synthesised from nucleotides 1-297 of the
published cDNA sequence (Vastrik et al., 1995) using T7
polymerase and [32P]UTP. The mouse fl-actin cRNA was
similarly synthesised from nucleotides 1188-1279 of the
published cDNA sequence (Tokunaga et al., 1986). After
purification in a 6% polyacrylamide/7 M urea gel, the
labelled transcripts were hybridised with 30,g of total
RNA overnight at 55°C. Single-stranded RNA was then
digested with RNAase Tl and RNAase A at 30°C and the
purified protected fragments were analysed in a 6%
polyacrylamide/7M urea gel.
Total RNA was isolated from wound tissue in the mice by
guanidium thiocyanate -phenol -chloroform extraction
(Chomczynski and Sacchi, 1987).
In situ hybridisation
The mouse Mad antisense and sense cRNA probes were
synthesised from linearised pBluescript II SK+ plasmid
(Stratagene, La Jolla, CA, USA), containing an ApaI-PstI
fragment from mouse Mad cDNA (nucleotides 301-1001),
via incorporation of [35S]UTP using T3 and T7 polymerases
(Amersham, Little Chalfont, UK). Mouse c-Myc antisense
and sense cRNA probes were synthesised in a similar manner
from linearised pmcxs plasmid (a kind gift from Drs Ronald
DePinho and Nicole Schreiber Agus), containing a 750 bp
XbaI-Sacl fragment from mouse c-Myc cDNA in pBlue-
script SK+ (Stratagene). The human Mad antisense and sense
cRNA probes were synthesised from linearised pGEM3Zf(+)
plasmid containing a PCR-amplified human Mad cDNA
insert (Vastrik et al., 1995), using T7 and SP6 polymerases
and [35S]UTP.
In situ hybridisation of paraffin sections was performed as






Figure 2 RNA in situ analysis of Mad expression in a healing epidermal wound. Darkfield (a, c and e) and lightfield (b, d and f)
exposures are shown. Section of a healing wound on day 3 after wounding hybridised with the Mad antisense probe, is shown in a
and b, on day 5 in c and d and on day 13 in e and f. The wound tissue on day 13 has disintegrated during the preparation of the
sample. Bar = 1 mm. W.....¢Y
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previously described (Wilkinson et al., 1987a,b) with the
following modifications: (1) instead of toluene, xylene was
used before embedding in paraffin wax; (2) cut sections were
placed on a layer of diethylpyrocarbonate-treated water on
the surface of glass slides pretreated with 2% 3-triethoxy-
silylpropylamine; (3) alkaline hydrolysis of the probes was
omitted; (4) the hybridisation mixture contained 60%
deionised formamide; (5) the high-stringency wash was
for 105 min at 65°C in a solution containing 50 mm DTT
and 1 x SSC. The sections were coated with NTB-2
emulsion (Kodak) and stored at 4°C. The slides were
exposed for 21 days, developed and stained with
haematoxylin. Control hybridisations with sense strand
and RNAase A-treated sections did not give a specific
signal above background.
Immunohistochemistry
Immunohistochemical examination of skin and tumour
specimens with antibodies against the core protein of
mouse syndecan-1, which served as an epithelial cell
differentiation marker was carried out using the avidin-
biotin immunoperoxidase method and paraformaldehyde-
fixed, paraffin-embedded material (Korhonen et al., 1984;
Elenius et al., 1991). After deparaffinisation and rehydration
of the tissue sections, endogenous peroxidase activity-was
blocked by incubating the slides in methanol containing
0.3% hydrogen peroxide for 30 min. The sections were then
incubated with normal rabbit serum diluted in phosphate-
buffered saline (PBS), for 30 min at room temperature. The
primary monoclonal antibody 281-2, which specifically
recognises the core protein of mouse syndecan-1, was used
(Jalkanen et al., 1985) at a concentration of 20 mg ml-' in
PBS and incubated overnight at 4°C. The slides were then
incubated with biotinylated rabbit anti-rat IgG at a 1:200
dilution in PBS for 40 min at room temperature and then
with avidin-biotin-peroxidase complex (Vectastain kit,
Vector Laboratories). Between each antibody incubation,
the slides were washed three times with PBS. Immobilised
peroxidase was visualised by incubation with 0.25 mg ml-'
of its substrate 3,3'-diaminobenzidine tetrahydrochloride
(DAB; Polysciences, Northampton, UK) in 0.05 M Tris-
HCl buffer, pH 8, containing 0.03% hydrogen peroxide for
5 min. Finally, the sections were counterstained with
haematoxylin and mounted (Aquamount; BDH, Poole,
UK). Antibodies against PCNA (Dako, Glostrup, Den-
mark) and p53 (a gift from Dr Allan Balmain, Glasgow,
UK) were used as described previously (Korhonen et al.,
1984).
Results
Mad is highly expressed in the suprabasal layer ofmouse
epidermis
As shown in the in situ hybridisation analysis of Figure 1,
Mad is highly expressed in the suprabasal layers of newborn
mouse skin (arrows in Figure la and b), and to a lesser extent
in adult mouse skin (Figure Ic and d). Basal epidermal cells
adjoining the basement membrane were consistently negative
as were the basal cell layers of the hair follicle and hair germ
cells (less than 10 grains per cell). No specific signal was
detected in stromal fibroblasts, vessels or other supporting
structures. Control sections hybridised with the Mad sense
strand did not give a specific signal above background either.
The degree of expression correlated directly with the relative
thickness of the epidermis in the various anatomical regions.
Therefore, in regions where the epidermis was thick, such as
dorsal skin, the signal was strong (Figure Ic and d) and
where the skin was thin, such as the ventral part, the signal
was barely visible (Figure le and f). In contrast, the c-Myc
mRNA was barely visible via in situ hybridisation in any
region of adult skin (Figure Ig and h), although it is
expressed in fetal skin (Hurlin et al., 1995).
Analysis of healing skin of full-thickness wounds via in
situ hybridisation showed an initial up-regulation of Mad
mRNA 3 days after wounding (Figure 2a and b) and a
subsequent strong expression at the edges of the wound on
days 5 (Figure 2c and d) and 7. By day 13, the expression had
decreased to levels equivalent to the unwounded adult mouse
epidermis (Figure 2e and f). Consistent with these results,
RNAase protection analysis of the wounds showed increased
accumulation of Mad mRNA with increasing thickness ofthe
differentiating epidermal keratinocyte layer, reaching a
maximum on day 7 of healing (Figure 3).
Mad in carcinogen-induced mouse skin tumours
Our previous studies suggested that Mad causes an inhibition
of cell growth in vitro (Vastrik et al., 1995). In order to study
if Mad expression is altered during skin carcinogenesis,
samples were taken from normal skin and from carcinogen-
exposed, hyperplastic and dysplastic lesions and squamous
cell carcinomas with varying degrees of differentiation. The
tumours were generated by repeated administration of
DMBA and samples were taken during the neoplastic
development and after the animal was sacrificed owing to
extensive neoplastic involvement. The lesions analysed
represented the entire spectrum of tumour progression, from
uninvolved skin to reversible hyperplasia and dysplasia
increasing in severity ultimately resulting in the formation
of squamous cell carcinomas, varying in differentiation from
well-differentiated, keratin-producing tumours to sarcoma-
like spindle cell neoplasms. Different morphological changes
varying in extent and severity were observed in single
samples.
Epidermal hyperplasia of carcinogen-treated skin consist-
ing of 5-15 layers of histologically regular, stratified and
polarised cells exhibited a distinct, enhanced signal in the
upper half of the epidermis (about 50-100 grains per cell)
(Figure 4a and b). The suprainfundibular part of the hair
follicles also had a distinct signal in the superficial cell layers,
whereas the basal cells were consistently negative. Epidermal
dysplasia with cytological irregularities and disturbed
stratification and polarisation showed a less intense signal
in the keratinocytes (arrows in Figure 4c and d). Only the
most superficial cells exhibited a strong Mad signal.
Downward extensions of cells surrounded by basement
membrane were negative (arrowhead in Figure 4c and d).







Figure 3 Mad mRNA in wound tissue during re-epithelialisa-
tion. RNAase protection analysis of RNA isolated from the skin
at the indicated times after wounding (1-7 days) and from
normal control skin (lane C). The size of the probe (lane P) and
the protected Mad fragment are indicated in base pairs; ,B-actin
was used as a control.Papillomas, benign neoplasms consisting of differentiated
regular cells, also showed distinct signals in the upper half of
the epidermis, absent in the basal cell layer.
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Well-differentiated (grade 1) squamous cell carcinomas
contained numerous keratinocytes strongly expressing Mad.
These cells were observed surrounding intratumoral horn
Figure 4 Mad expression in carcinogen-treated skin and carcinogen-induced skin tumours. a-d show a distinct Mad expression in
upper layers of hyperplastic epidermis, but reduced expression in dysplastic keratinocytes (arrows in c and d) and no expression in
downward extensions (arrowhead). (e and f) Numerous Mad-expressing cells surrounding horn cysts in well-differentiated squamous
cell carcinoma (arrows). (g and h) Epidermal cells show a distinct Mad signal (arrows), which is absent from the undifferentiated
squamous cell carcinoma in the dermis. Bar=0.1 mm.Mad expression in keratinocytes
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cysts, on the surface of epithelial excrescences and on the
inner surface of epidermal invaginations (arrows in Figure 4e
and f). PCNA-positive proliferating cells and cell layers
adjoining the basement membrane were consistently negative
for Mad (data not shown). In contrast, poorly differentiated
sarcoma-like squamous cell carcinomas exhibited no Mad
mRNA, although the adjoining normal epidermis contained
cells with a distinct signal (arrows in Figure 4g and h). Weak
Mad signal was also detected inside the sebaceous glands
(arrowhead in Figure 4g and h). The anaplastic cells, showing
only focal keratin expression, were abundantly positive for
PCNA and p53 (data not shown).
In order to monitor keratinocyte differentiation in the
tumours, the expression of epithelial syndecan-1, which is
known to decrease during tumorigenesis, was analysed in the
same skin lesions via immunoperoxidase staining. Syndecan-
1, like Mad, was most abundantly expressed in the
differentiating suprabasal layers of epidermis and in the
dermal hair follicle cysts, whereas the dermis was negative.
No specific signal was observed in the sections stained with
control antibody (data not shown). Hyperplastic DMBA-
treated epidermis showing elongated rete ridges, exhibited
distinct syndecan-1 staining that was slightly discontinuous
and irregular, whereas the basal cell layer and the superficial
differentiated epidermal cell layer were negative (Figure 5a
and b). In dysplastic areas, atypical keratinocytes showed
intensive staining, while the basal cell layer was negative
(Figure Sc). Some syndecan-1 expression was seen, in the
well-differentiated areas of the squamous cell carcinomas
where keratin horn cysts were formed (Figure 5c), whereas
the expression was lost in the poorly differentiated areas of
these tumours (Figure 5d).
Mad expression in human squamous cell carcinoma, basal cell
carcinoma and melanoma
The human squamous cell carcinoma biopsies showed
hyperkeratosis, parakeratosis, hyperplastic epidermis with
cell dysplasia and various degrees of differentiation including
horn cyst formation and invasion in the dermis. Strong Mad
signals were detected in the thickened stratum granulosum
and in the cells around the horn cysts (Figure 6a and b).
Superficial spreading-type basal cell carcinomas showed
distinct Mad expression in the stratum granulosum but the
peripheral palisading basal carcinoma cells were negative.
Autoradiographic grains were present in keratotic basal cell
carcinomas forming horn cysts and also in the cells
surrounding these cysts, which are considered to represent
incomplete hair shaft formation (Figure 6c and d). No Mad
expression was detected in nodular melanoma (data not
shown). The biopsies also contained areas ofadjacent normal
healthy skin, where the Mad expression pattern was observed
to be similar to that of normal adult mouse skin (Figure 6e
and f). Mad expression was also noted inside the sebaceous
glands and in the keratinocytes surrounding the lumen of the
hair shafts (data not shown). Sections of normal human skin
hybridised with the Mad sense strand gave only background
unspecific signal from the most superficial keratin layers
(inset Figure 6e).
Figure 5 Immunostaining for syndecan-1 in carcinogen-treated
skin and carcinogen-induced skin tumours. (a and b) Distinct
syndecan-1 staining in the suprabasal epidermal layers in
hyperplastic epidermis. In the horn cysts in well-differentiated
squamous cell carcinoma (c), syndecan-1 staining is decreased and
restricted to the differentiating cells, whereas in the dysplastic
areas only very weak staining can be detected. Epidermal cells (d)
stain positively for syndecan-I while the undifferentiated
anaplastic squamous cell carcinoma cells in the dermis are
negative. The lesions stained were obtained from the same
samples as-those shown in Figure 4. Bar=0.1 mm.Mad expression in keratinocytes
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Figure 6 Mad expression in human squamous and basal cell carcinomas. (a and b) Intensive Mad signal in the stratum granulosum
in a squamous cell carcinoma and in the cells that form a horn cyst, which is seen only partially in the lower part of the figure
(arrows in a and b). In the upper layers of the skin hyperkeratosis, parakeratosis and necrotic keratinocytes can be detected
(arrowheads in a and b; the skin surface is just beyond the upper margin of the figure). (c and d) A keratotic basal cell carcinoma
forming horn cysts. Strong Mad signal is found in the keratinocytes surrounding the horn cyst (arrow). (e and f) Hybridisations of
normal human adult skin with the Mad antisense probe; the inset in e shows control hybridisation with the Mad sense probe.
Bar =0.Imm.
Discussion
In this study we have observed that Mad mRNA is highly
expressed in differentiating epidermal keratinocytes in normal
epidermis, healing skin wounds and epidermal tumours,
whereas the proliferating basal epidermal cells are negative.
This localised expression supports the hypothesis that Mad is
associated with cell differentiation. Analogous results have
been published for leukaemia cell lines differentiating in
culture (Ayer and Eisenman, 1993; Larsson et al., 1994;
Zervos et al., 1993). However, unlike leukaemia cells in
culture, the proliferating and differentiating epidermal
keratinocytes expressed little or no c-Myc, suggesting that
steady-state c-Myc mRNA levels, even in proliferating cells,
are significantly lower than Mad mRNA levels in the
differentiating cells. This result is of interest, as Mad is
currently held to lack intrinsic functional activity and
believed to function only as an antagonist of Myc and a
repressor of Myc-regulated genes in a ternary complex with
Max and the mammalian homologues of the yeast repressor
Sin3 (Ayer et al., 1995). Clearly, other members of the myc
gene family may interact with Mad in the epidermal
keratinocytes. It should also be mentioned that two recently
discovered Max-interacting bHLHZip proteins, Mad3 and
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Mad4, are related to Mad and MxiI and that the
heterocomplexes Mad3-Max, Mad4-Max repress transcrip-
tion by binding to the same E-box-like sequences that
mediate Myc-Max activation (Hurlin et al., 1995).
Differentiating cells in hyperplastic lesions and cells
surrounding horn cysts in well-differentiated squamous cell
carcinomas strongly expressed Mad mRNA. Dysplastic
epidermal cells, although benign and with a preserved
basement membrane, expressed only low levels of Mad.
Mad was therefore observed in benign as well as in malignant
lesions. A few of the most malignant lesions that had lost the
structure of epidermal stratification and differentiation were
negative for Mad. However, even in the presence of a Mad
mRNA signal, the possibility remains that the mad gene has
suffered small mutations in critical regions, for example in the
region encoding the 25 first amino acid residues, which are
important for its function as a transcriptional repressor (Ayer
et al., 1995) and presumably as an inhibitor of cell growth
(Vastrik et al., 1995).
The expression pattern of Mad was different from that of
syndecan-1, which began in a deeper epidermal layer and also
extended to the rete ridges. However, there was significant
correlation of Mad and syndecan-1 expression in the skin
tumours in relation to their degree of malignancy. Syndecan-
1 is known to be down-regulated in the most malignant skin
lesions (Inki et al., 1994), possibly owing to the loss of
epidermal layered cytoarchitecture. Thus, syndecan-1 pro-
vides a marker for the loss of epidermal cell differentiation
associated with malignant progression, and our studies show
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